Market Analysis - Sep&Oct, 2020 - Oseltamivir Phosphate Product&Shikimic Acid

 Market Analysis - Annual Report -September, 2020- Oseltamivir Phosphate Product

1.Overview of the Current Market Situation

OSELTAMIVIR phosphate is recognized as one of the most effective drugs against avian influenza and H1N1 virus. As we all know, the original oseltamivir drug is Roche's "Tamiflu" (Oseltamivir phosphate), patented in 2017 maturity. It was approved for marketing by the US FDA in 1999, and it was listed in China in 2004. It is currently on the market in more than 60 countries and regions around the world. It is recognized as one of the most effective anti-flu drugs in the world. According to relevant data, the H5N1 global avian influenza outbreak in 2005 resulted in a substantial increase in orders from countries around the world, and Roche's production capacity was insufficient. To meet the needs of the epidemic, Roche was under pressure to release patent authorization.

The main participants in the international pharmaceutical market are F. Hoffmann-La Roche Ltd., NATCO Pharma Limited, Tea Pharmaceutical Industries Ltd., LUPINE Limited, Amneal Pharmaceuticals LLC, Zydus Cadila, Sun Pharmaceutical Industries Ltd., Alembic Pharmaceuticals Limited, Mylan NV etc. The main manufacturers with better qualifications in China are Yichang Dongyangyang Yangtze River Pharmaceutical Co., Ltd., Borui Pharmaceutical (Suzhou) Co., Ltd., Jiangsu Nuotai Aosinuo Biopharmaceutical Co., Ltd. and Yangling Jitai Pharmaceutical Co., Ltd. It can be seen that more and more pharmaceutical companies have joined this ranks, and most of them are partners of ECHEMI GROUP.

2.Forecast of the Future Market Situation

Although the market is dominated by North America, some experts predict that it will be replaced by the Asia-Pacific market by the end of 2027. Due to the high prevalence of influenza and the increase in FDA-approved drugs, the Tamiflu drug market in North America has been growing positively. Due to major market players, Europe is considered to be the second largest growing regional market, and there is an increasing focus on mental health. Due to the development of healthcare facilities, a large number of generic drug manufacturers, as well as government programs and expert groups, the Asia-Pacific region is expected to Lead the market.

It should be noted that seasonal influenza epidemics mainly occur in winter. The northern hemisphere will soon enter winter. Oseltamivir phosphate is recognized as one of the most effective anti-flu drugs. The market demand will change significantly in the next quarter, so we can focus on it.

Market Analysis - Annual Report -October, 2020- Shikimic Acid

1.Overview of the product description

In the past few years, antiviral drugs have grown from a small variety on the international pharmaceutical market to a large category. Oseltamivir phosphate has become the main international anti-influenza product, and it is difficult for other influenza drugs to shake its monopoly. The key raw material for the production of oseltamivir phosphate is shikimic acid. Shikimic acid is a monomer compound extracted from the fruits of the genus Illicium. Shikimic acid can directly affect the metabolism of arachidonic acid, inhibit platelet aggregation, and inhibit the formation of arterial and venous thrombosis and cerebral thrombosis. Shikimic acid also has anti-inflammatory and analgesic effects. Shikimic acid can be used as an anti-viral and anti-cancer drug intermediate. In the body, shikimic acid can also be transformed into a variety of substances that have inhibitory effects on viruses, bacteria and cancer cells. Modern pharmacological studies have also proved that shikimic acid and its derivatives have anti-inflammatory, analgesic, anti-tumor, anti-thrombotic, and anti-cerebral ischemia effects. What is striking is that shikimic acid is a key raw material for the synthesis of anti-avian influenza drug oseltamivir. In addition, shikimic acid has a wide range of uses in medicine, cosmetics and other industries.

2.Forecast of the Future Market Situation

The major global manufacturer is Shionoyoshi Pharmaceutical Co., Ltd. of Japan. Shinoyoshi's shikimic acid synthesis plant mainly provides raw materials of oseltamivir for Roche. Major domestic production companies include Shaanxi Jiahe Biotechnology Co., Ltd., Guilin Rhine Biotechnology Co., Ltd., etc. Several large companies export shikimic acid to foreign countries in a monopoly.

With the growth of domestic and foreign market demand, the domestic annual output of shikimic acid is increasing year by year, and it is expected to reach more than 130 tons in 2020. With the substantial reduction in the production of raw anise, the price fluctuates greatly. This phenomenon greatly reduces the profits of the manufacturers. Therefore, while ensuring the annual output, the price of shikimic acid will also increase from a small increase to a large increase, which explains Mang Reasons for oxalic acid price fluctuations. The following figure attaches a chart of changes in shikimic acid production over the years.